Did the FDA approve Lisraya as the first oral dermatomyositis treatment?

Yes. On August 27, 2026, the FDA approved Priovant’s Lisraya (brepocitinib) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment for the disease. The once-daily JAK/TYK2 inhibitor was backed by a phase 3 trial showing better improvement scores than placebo, but it carries a boxed warning for serious safety risks.